THEONCOLOGYNURSE.COM: Keyword Density Checker

Total words: 4312 | 2-word phrases: 1121 | 3-word phrases: 1203 | 4-word phrases: 1243

PAGE INFO

Title	Try to keep the title under 60 characters (18 characters) The Oncology Nurse
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	in patients with	8	0.67%
2	2023vol 16 no	6	0.50%
3	vol 17 no	5	0.42%
4	view more articles	4	0.33%
5	patients with her2	4	0.33%
6	data from asco	4	0.33%
7	2024vol 17 no	3	0.25%
8	or refractory follicular	3	0.25%
9	the patient experience	3	0.25%
10	refractory follicular lymphoma	3	0.25%
11	patients with advanced	3	0.25%
12	17 no 3	3	0.25%
13	hunterdon regional cancer	3	0.25%
14	regional cancer center	3	0.25%
15	epkinly to treat	2	0.17%
16	ongoing phase 3	2	0.17%
17	phase 3 randomized	2	0.17%
18	3 randomized trial	2	0.17%
19	randomized trial beamion	2	0.17%
20	trial beamion lung2	2	0.17%
21	beamion lung2 of	2	0.17%
22	lung2 of zongertinib	2	0.17%
23	for epkinly to	2	0.17%
24	standard of care	2	0.17%
25	versus standard of	2	0.17%
26	by patricia stewart	2	0.17%
27	of care in	2	0.17%
28	care in patients	2	0.17%
29	with advanced nsclc	2	0.17%
30	advanced nsclc harboring	2	0.17%

#	Keyword	Frequency	Density
1	in patients with her2	4	0.32%
2	in patients with advanced	3	0.24%
3	hunterdon regional cancer center	3	0.24%
4	vol 17 no 3	3	0.24%
5	or refractory follicular lymphoma	3	0.24%
6	of beamion lung1 a	2	0.16%
7	relapsed or refractory follicular	2	0.16%
8	her2 aberrationpositive solid tumors	2	0.16%
9	with her2 aberrationpositive solid	2	0.16%
10	patients with her2 aberrationpositive	2	0.16%
11	zongertinib in patients with	2	0.16%
12	to treat patients with	2	0.16%
13	phase 1a1b trial of	2	0.16%
14	a phase 1a1b trial	2	0.16%
15	lung1 a phase 1a1b	2	0.16%
16	beamion lung1 a phase	2	0.16%
17	exposureresponse analysis of trastuzumab	2	0.16%
18	asco of beamion lung1	2	0.16%
19	catherine bishop dnp npc	2	0.16%
20	bishop dnp npc aocnp	2	0.16%
21	from asco of beamion	2	0.16%
22	data from asco of	2	0.16%
23	updated data from asco	2	0.16%
24	epkinly to treat patients	2	0.16%
25	for epkinly to treat	2	0.16%
26	approval for epkinly to	2	0.16%
27	second approval for epkinly	2	0.16%
28	granted second approval for	2	0.16%
29	deruxtecan to inform dosing	2	0.16%
30	cancer center committed to	2	0.16%
31	by catherine bishop dnp	2	0.16%
32	ongoing phase 3 randomized	2	0.16%
33	phase 3 randomized trial	2	0.16%
34	september 2024 vol 17	2	0.16%
35	2024 exposureresponse analysis of	2	0.16%
36	asco 2024 exposureresponse analysis	2	0.16%
37	from asco 2024 exposureresponse	2	0.16%
38	data from asco 2024	2	0.16%
39	to inform dosing in	2	0.16%
40	inform dosing in patients	2	0.16%

#	URL	Whois	Check
1	https://conference-correspondent.com/?utm_source=TON	Whois	conference-correspondent.com
2	https://conference-correspondent.com/highlights/esmo/esmo-2024?utm_source=TON	Whois	conference-correspondent.com
3	https://aonnonline.org/continuing-education/modules	Whois	aonnonline.org
4	https://conference-correspondent.com/?utm_source=TON	Whois	conference-correspondent.com
5	https://conference-correspondent.com/highlights/esmo/esmo-2024?utm_source=TON	Whois	conference-correspondent.com
6	https://aonnonline.org/continuing-education/modules	Whois	aonnonline.org
7	https://amplity.com/privacy	Whois	amplity.com
8	https://www.amplity.com/privacy/	Whois	amplity.com